论文部分内容阅读
目的探讨吉非替尼单药治疗男性晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法男性NSCLCⅣ期患者59例,其中腺癌、细支气管肺泡癌占86.4%,既往化疗2个方案以上者占66.1%。口服吉非替尼至病情进展或出现不可耐受不良反应。患者分别于治疗1个月、治疗3个月、治疗3个月以后每隔2个月复查。结果59例患者均可评价疗效,无完全缓解患者,部分缓解14例,稳定10例,进展35例,有效率为23.7%,稳定率为16.9%,疾病控制率为40.7%。中位肿瘤进展时间为1.8个月。中位生存时间为8.5个月,生存时间与最佳疗效及一般状况有关。1、2和3年生存率分别为42.4%、17.1%和13.3%。常见不良反应为皮肤改变和腹泻,多为1、2度。结论吉非替尼单药治疗男性晚期NSCLC疗效明确,疾病控制后患者生存时间延长,不良反应较易耐受,是二线、三线用药的良好选择。
Objective To investigate the efficacy and safety of gefitinib monotherapy in the treatment of male patients with advanced non-small cell lung cancer (NSCLC). Methods Fifty-nine patients with stage Ⅳ NSCLC were enrolled, of which 86.4% were adenocarcinoma and bronchioloalveolar carcinoma, and 66.1% were those with two chemotherapy regimens. Gefitinib orally to the disease progression or intolerable adverse reactions. Patients were treated for 1 month, 3 months treatment, 3 months after treatment, review every 2 months. Results All the 59 patients could evaluate the curative effect without complete remission. The partial response was relieved in 14 cases, stabilized in 10 cases and progressed in 35 cases. The effective rate was 23.7%, the stability rate was 16.9% and the disease control rate was 40.7%. The median tumor progression time was 1.8 months. The median survival time was 8.5 months, survival time and the best effect and the general situation. The 1, 2 and 3-year survival rates were 42.4%, 17.1% and 13.3%, respectively. Common adverse reactions are skin changes and diarrhea, mostly 1, 2 degrees. Conclusion The efficacy of gefitinib monotherapy in the treatment of advanced NSCLC in men is clear. After the disease is controlled, the survival time of patients with NSCLC is prolonged and the adverse reaction is easy to be tolerated. It is a good choice for second and third-line treatment.